Microbiology Testing Managed Service

2026-11-03

SNBTS collects approximately 160,000 blood and tissue donations each year, these are tested at the Jack Copland Centre in Edinburgh within the Manufacturing Department of SNBTS. The Manufacturing Department performs a wide range of testing services; these include the large-scale serological screening of blood and tissue donations for microbiological markers such as HBsAg, HCV, HIV and Syphilis. Discretionary testing of HTLV, HBc and CMV. There is also a requirement for smaller scale screening for malaria antibodies on selected donations.SNBTS also requires a solution to allow archiving of samples.After testing, the whole of the remaining PPT tube is archived. Hard copy of the result data is also retained for thirty (30) years. The electronic copy of the raw test data is maintained in archive databases and retained indefinitely. SNBTS is currently using “Item Tracker” (archiving database). The Supplier MUST provide a solution for creating appropriate plate maps for integration into “Item Tracker” in such a way that the sample is later retrievable.During the course of the contract SNBTS may look to introduce additional testing/protocols into the contract. This would be in relation to the introduction of any new mandatory/discretionary markers. This would be fully discussed with the successful Supplier and SNBTS would expect the Supplier to provide options for inclusion in the contract.Future Potential ImpactsSNBTS in line with other Blood Authorities will be starting to collect plasma for medicines (PFM) since the option to fractionate UK plasma has opened again.PFM is expected to be 5 year phased implementation with minimal impact in the early years of the contract. (Up to 10% increase). SNBTS will update and work with the successful supplier or bidders where information is available throughout the process where known. Beyond 5 years there is likely to be a larger increase that will increase the contract.Additional QC testing may be required as an impact of implementation of plasma for medicines. Dependant on the volume of testing SNBTS may wish to cease outsourcing of Total protein testing and source a suitable platform for use within SNBTS. Figures for this have yet to be defined however SNBTS would like to enter discussions to see if operationally it is viable to bring this in house. It is expected that this would be able to be accommodated with a modification of any contract put in place due to the estimated value of this testing.CPV: 50421000.

United Kingdom (UK)

2026-07-24